Complications of pancreatic cancer resection

Digestive Surgery

Volumn 19, Issue 2, 2002, Pages 138-146

  Halloran, C M ^a   Ghaneh, P ^a   Bosonnet, L ^a   Hartley, M N ^a   Sutton, R ^a   Neoptolemos, John P ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Morbidity; Mortality; Pancreatic cancer; Post operative complications; Re operation rate; Resection

Indexed keywords

OCTREOTIDE; SOMATOSTATIN;

ABDOMINAL ABSCESS; BLEEDING; CANCER INCIDENCE; CANCER SURGERY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FISTULA; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; MULTICENTER STUDY; PANCREAS CARCINOMA; POSTOPERATIVE COMPLICATION; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; STOMACH EMPTYING; SURVIVAL; TREATMENT OUTCOME; WOUND INFECTION;

ANASTOMOSIS, SURGICAL; GASTRIC EMPTYING; GASTROINTESTINAL AGENTS; HUMANS; LENGTH OF STAY; OCTREOTIDE; PANCREATECTOMY; PANCREATIC FISTULA; PANCREATIC NEOPLASMS; REOPERATION; TREATMENT OUTCOME;

EID: 0036241204     PISSN: 02534886     EISSN: None     Source Type: Journal    
DOI: 10.1159/000052029     Document Type: Conference Paper

References (97)

1. Cancer statistics
2. Cancer of the pancreas. Fifty years of surgery
3. Pancreatic ductal adenocarcinoma surgery
4. Patterns of growth and metastases of induced pancreatic cancer in relation to prognosis and its clinical implications
5. Lymph node involvement in carcinoma head of pancreas
6. Pancreatic cancer resectional outcomes in American university centers 1988-1990
7. Long-term survival after curative resection for pancreatic ductal adenocarcinoma: Clinical-pathological analysis of 5-year survivors
8. Pancreatoduodenectomy with or without extended retroperitoneal lymphadectomy for periampullary adenocarcinoma: Comparison of morbidity and mortality and short-term exposure
9. Factors influencing morbidity and mortality after pancreaticoduodenectomy: Critical analysis of 221 resections
10. One hundred and forty-five consecutive pancreatoduodenectomies without mortality
11. Low mortality following resection for pancreatic and periampullary tumours in 1,026 patients: UK survey of specialist pancreatic units
12. Surgical resection for cancer of the pancreas
13. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality
14. Resection of pancreatic cancer. Surgical achievements
15. Resection for pancreatic cancer: The Japanese experience
16. Six hundred and fifty consecutive pancreaticoduodenectomies in the 1990s
17. Rates of complications and death after pancreatoduodenectomy: Risk factors and the impact of hospital volume
18. Adjuvant chemotherapy in pancreatic cancer
19. A randomised controlled trial of adjuvant immunotherapy (murine monoclonal antibody 493/32) in resectable pancreatic cancer
20. Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer
21. Treatment of duct carcinoma of the pancreas with the LH-RH analogue Buserelin
22. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomised controlled trial
23. Cancer treatment policies and their effect on survival - Pancreas
24. Improved hospital morbidity, mortality and survival after the Whipple procedure
25. Pancreatic cancer: A report of treatment and survival trends for 100,313 patients diagnosed from 1985 to 1995, using the National Cancer Database
26. Pancreaticoduodenectomy: Forty-one consecutive Whipple resections without an operative mortality
27. The surgical treatment of pancreatic carcinoma
28. Pyloric preservation with the Whipple procedure
29. Decreased morbidity and mortality after pancreatoduodenectomy
30. Pyloric and gastric preserving pancreatic resection. Experience with 87 patients
31. An analysis of the reduced morbidity and mortality rates after pancreaticoduodenectomy
32. Complications following pancreaticoduodenectomy. Current management
33. Complications and outcome in the treatment of pancreatic adenocarcinoma in the United States veterans
34. Surgical treatment of pancreatic cancer
35. Pancreatic resection for carcinoma of the pancreas: Whipple versus total pancreatectomy - An institutional perspective
36. Complications requiring reoperation following pancreatectomy
37. Standards for pancreatic resection in the 1990s
38. Resection of the pancreatic head with or without gastrectomy
39. Outcome of microscopic nonradical, subtotal pancreatoduodenectomy (Whipple resection) for treatment of pancreatic head tumours
40. Survival after resection for ductal adenocarcinoma of the pancreas
41. Adenocarcinoma of the ampulla of Vater. A 28-year experience
42. Long-term survival after resection for ductal adenocarcinoma of the pancreas
43. Factors influencing morbidity and mortality in pancreatoduodenectomy
44. Morbidity and mortality after radical and palliative pancreatic cancer surgery. Risk factors influencing the short-term results
45. Pylorus preserving pancreatoduodenectomy. Is it an adequate cancer operation
46. A report of forty-four instances of pancreatoduodenal resection in patients more than seventy years of age
47. Prognostic indicators for survival after resection of pancreatic adenocarcinoma
48. Successful pancreatojejunual anastomosis for pancreatoduodenectomy
49. Pancreatic fistula after pancreatic head resection
50. Pancreatic cancer: Matters for debate. The standard diagnostic work-up and surgical treatment of pancreatic head tumours
51. Prevention and treatment of complications in pancreatic cancer surgery
52. Pancreatoduodenectomy for cancer of the head of the pancreas
53. Invasive treatment of pancreatic fluid collections with surgical and nonsurgical methods
54. Percutaneous management of pancreatic fluid collections
55. Percutaneous abscess drainage: Current applications for critically ill patients
56. Percutaneous abscess drainage: Update
57. Haemorrhage after pancreatoduodenectomy
58. Arterial haemorrhage after pancreatoduodenectomy. The 'sentinal bleed'
59. Delayed massive haemorrhage after pancreatic and surgery
60. Haemorrhage in pancreatic disease
61. Pancreatic anastomotic leak after pancreaticoduodenectomy: Incidence, significance and management
62. Are pancreatic anastomoses improved by duct-to-mucosa sutures?
63. Optimal management of the pancreatic remnant after pancreaticoduodenectomy
64. Pancreatoduodenectomy with pylorus preservation for adenocarcinoma of the head of pancreas
65. Management of the pancreatic stump following pancreaticoduodenectomy
66. Pancreatoduodenectomy with occlusion of the residual stump by Neoprene injection
67. Concomitant benefit of preoperative irradiation in preventing pancreas fistula formation after pancreatoduodenectomy
68. Purse-string pancreatico-jejunostomy following pancreatic resection
69. Somatostatin in the management of gastrointestinal fistulas. A multicentre trial
70. Randomised double-blind placebo-controlled trial of early octreotide in patients with post-operative enterocutaneous fistula
71. Treatment of 27 postoperative enterocutaneous fistulas with long half-life somatostatin analogue SMS 201-995
72. Role of octreotide in the treatment of external pancreatic pure fistula: A single-institution prospective experience
73. Complicated enterocutaneous fistula: Failure of octreotide to improve healing
74. Risk analysis of fistula after pancreatic head resection
75. Incidence, risk factors and treatment of pancreatic leakage after a pancreatoduodenectomy: Drainage versus resection of pancreatic remnant
76. Completion pancreatectomy for complications after pancreatoduodenectomy
77. Erythomycin accelerates gastric emptying after pancreatoduodenectomy
78. Delayed gastric emptying after standard pancreatoduodenectomy versus pylorus preserving pancreatoduodenectomy: An analysis of 200 consecutive patients
79. Comparison between pylorus preserving and Whipple pancreatoduodenectomy
80. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: A multi-centre, prospective, randomised study
81. Inhibition by somatostatin of pancreatic juice and enzyme secretion and gallbladder contraction in man induced by secretin and cholecystokinin-pancreozymin administration
82. Effects of somatostatin on the exocrine pancreas and the release of duodenal hormones
83. Role of octreotide in the prevention of postoperative complications following pancreatic resection
84. Efficacy of octreotide in the prevention of complications of elective pancreatic surgery
85. Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections: A prospective, controlled, randomised clinical trial
86. Prospective, randomised trial of octreotide to prevent pancreatic fistula after pancreatoduodenectomy for malignant disease
87. Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreatoduodenectomy? Results of a prospective randomised placebo-controlled trial
88. Randomised controlled multicentre study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitis
89. Randomised controlled multicentre trial of somatostatin infusion after pancreatoduodenectomy
90. Cost and outcome of the Whipple procedure
91. The effect of regionalization on cost and outcome for one general high-risk surgical procedure
92. Economic evaluation of the use of octreotide for prevention of complications following pancreatic resection
93. Statewide regionalization of pancreaticoduodenectomy and its effect on in-hospital mortality
94. Relation of preoperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy
95. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: An epidemiological study
96. Should we concentrate pancreatoduodenectomies to fewer hospitals in Finland?
97. Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy